{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:11:53Z","timestamp":1789949513368,"version":"4.0.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s40264-018-00783-1","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T13:23:39Z","timestamp":1551705819000},"page":"617-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Benefit\u2013Risk Assessment of Vedolizumab in the Treatment of Crohn\u2019s Disease and Ulcerative Colitis"],"prefix":"10.1007","volume":"42","author":[{"given":"Robert","family":"Battat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"783_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","volume":"13","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24\u201330.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"783_CR2","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","volume":"132","author":"SR Targan","year":"2007","unstructured":"Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672\u201383.","journal-title":"Gastroenterology"},{"issue":"18","key":"783_CR3","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2005;353(18):1912\u201325.","journal-title":"N Engl J Med"},{"issue":"14","key":"783_CR4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/jama.2009.451","volume":"301","author":"BM Kuehn","year":"2009","unstructured":"Kuehn BM. Rare neurological condition linked to newer monoclonal antibody biologics. JAMA. 2009;301(14):1423\u20134.","journal-title":"JAMA"},{"issue":"11","key":"783_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","volume":"361","author":"Y Chen","year":"2009","unstructured":"Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361(11):1067\u201374.","journal-title":"N Engl J Med"},{"issue":"1","key":"783_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/practneurol-2011-000092","volume":"12","author":"D Hunt","year":"2012","unstructured":"Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol. 2012;12(1):25\u201335.","journal-title":"Pract Neurol."},{"issue":"3","key":"783_CR7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"783_CR8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","volume":"153","author":"DJ Erle","year":"1994","unstructured":"Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol. 1994;153(2):517\u201328.","journal-title":"J Immunol."},{"issue":"11","key":"783_CR9","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/ibd.22940","volume":"18","author":"ER Fedyk","year":"2012","unstructured":"Fedyk ER, Wyant T, Yang L-L, Csizmadia V, Burke K, Yang H, et al. Exclusive antagonism of the \u03b14\u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18(11):2107\u201319.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"783_CR10","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","volume":"190","author":"KG Haanstra","year":"2013","unstructured":"Haanstra KG, Hofman SO, Est\u00eav\u00e3o DML, Blezer EL, Bauer J, Yang L-L, et al. Antagonizing the \u03b14\u03b21 integrin, but not \u03b14\u03b27, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013;190(5):1961\u201373.","journal-title":"J Immunol."},{"key":"783_CR11","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1097\/00054725-201112002-00173","volume":"17","author":"C Milch","year":"2011","unstructured":"Milch C, Wyant T, Xu J, Kent W, Berger J, Fox I. Vedolizumab does not reduce the CD4\u2009+\u2009: CD8\u2009+\u2009ratio in the CSF of healthy volunteers: P-136. Inflamm Bowel Dis. 2011;17:S54.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"783_CR12","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","volume":"148","author":"B Bressler","year":"2015","unstructured":"Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035\u20131058.e3.","journal-title":"Gastroenterology"},{"issue":"1","key":"783_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/j.gastro.2015.05.036","volume":"149","author":"T Dassopoulos","year":"2015","unstructured":"Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology. 2015;149(1):238\u201345.","journal-title":"Gastroenterology"},{"issue":"18","key":"783_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713\u201325.","journal-title":"N Engl J Med"},{"issue":"4","key":"783_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Reviews Gastroenterol Hepatol. 2015;12(4):205\u201317.","journal-title":"Nat Reviews Gastroenterol Hepatol."},{"issue":"2","key":"783_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ajg.2011.386","volume":"107","author":"A Bitton","year":"2012","unstructured":"Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: toronto consensus statements. Am J Gastroenterol. 2012;107(2):179\u201394.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"783_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","volume":"19","author":"MW Lutgens","year":"2013","unstructured":"Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789\u201399.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"783_CR18","doi-asserted-by":"publisher","first-page":"A874","DOI":"10.1016\/S0016-5085(00)85637-1","volume":"118","author":"BG Feagan","year":"2000","unstructured":"Feagan BG, McDonald J, Greenberg G, Wild G, Pare P, Fedorak RN, et al. An ascending dose trial of a humanized A4 B7 antibody in ulcerative colitis (UC). Gastroenterology. 2000;118(4):A874.","journal-title":"Gastroenterology"},{"issue":"24","key":"783_CR19","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa042982","volume":"352","author":"BG Feagan","year":"2005","unstructured":"Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352(24):2499\u2013507.","journal-title":"N Engl J Med"},{"issue":"8","key":"783_CR20","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ibd.21896","volume":"18","author":"A Parikh","year":"2012","unstructured":"Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"783_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","volume":"19","author":"A Parikh","year":"2013","unstructured":"Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"783_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"2","key":"783_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","volume":"15","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229\u201339.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"783_CR24","doi-asserted-by":"publisher","first-page":"S602","DOI":"10.1016\/S0016-5085(17)32150-9","volume":"152","author":"EV Loftus","year":"2017","unstructured":"Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, et al. Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. Gastroenterology. 2017;152(5):S602.","journal-title":"Gastroenterology"},{"issue":"5","key":"783_CR25","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1097\/MIB.0000000000000396","volume":"21","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(5):1151\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"783_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","volume":"12","author":"T Engel","year":"2018","unstructured":"Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis. 2018;12(2):245\u201357.","journal-title":"J Crohns Colitis."},{"issue":"6","key":"783_CR27","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","volume":"62","author":"JR Allegretti","year":"2017","unstructured":"Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, et al. Predictors of clinical response and remission at 1\u00a0year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab. Dig Dis Sci. 2017;62(6):1590\u20136.","journal-title":"Dig Dis Sci"},{"issue":"6\u20137","key":"783_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","volume":"52","author":"C Eriksson","year":"2017","unstructured":"Eriksson C, Marsal J, Bergemalm D, Vigren L, Bjork J, Eberhardson M, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52(6\u20137):722\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"783_CR29","doi-asserted-by":"publisher","first-page":"1593.e2","DOI":"10.1016\/j.cgh.2016.02.016","volume":"14","author":"A Amiot","year":"2016","unstructured":"Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593.e2\u20131601.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"783_CR30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/apt.13594","volume":"43","author":"DC Baumgart","year":"2016","unstructured":"Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2013a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43(10):1090\u2013102.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"783_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","volume":"10","author":"EE Vivio","year":"2016","unstructured":"Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, et al. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. J Crohns Colitis. 2016;10(4):402\u20139.","journal-title":"J Crohns Colitis."},{"issue":"9","key":"783_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","volume":"113","author":"N Narula","year":"2018","unstructured":"Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345\u201354.","journal-title":"Am J Gastroenterol"},{"issue":"10114","key":"783_CR33","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769\u201378.","journal-title":"Lancet"},{"issue":"4","key":"783_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","volume":"8","author":"J Cosnes","year":"2002","unstructured":"Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn\u2019s disease. Inflamm Bowel Dis. 2002;8(4):244\u201350.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"783_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3109\/00365529509096316","volume":"30","author":"P Munkholm","year":"1995","unstructured":"Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn\u2019s disease patients. Scand J Gastroenterol. 1995;30(7):699\u2013706.","journal-title":"Scand J Gastroenterol"},{"issue":"9853","key":"783_CR36","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605.","journal-title":"Lancet"},{"issue":"12","key":"783_CR37","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","volume":"6","author":"BG Feagan","year":"2008","unstructured":"Feagan BG, Greenberg GR, Wild G, Fedorak RN, Par\u00e9 P, McDonald JWD, et al. Treatment of active Crohn\u2019s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"783_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"783_CR39","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment had failed. Gastroenterology. 2014;147(3):618\u2013627 e3.","journal-title":"Gastroenterology."},{"issue":"1","key":"783_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","volume":"23","author":"BE Sands","year":"2017","unstructured":"Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97\u2013106.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"783_CR41","first-page":"S601","volume":"152","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, et al. Long-term effectiveness and safety of vedolizumab in patients with Crohn\u2019s disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. Gastroenterology. 2017;152(5):S601.","journal-title":"Gastroenterology"},{"issue":"8","key":"783_CR42","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/ajg.2016.236","volume":"111","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147\u201355.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"783_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/apt.14919","volume":"48","author":"PG Kotze","year":"2018","unstructured":"Kotze PG, Ma C, Almutairdi A, Al-Darmaki A, Devlin SM, Kaplan Gilaad G, et al. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(6):626\u201337.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"783_CR44","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/apt.14550","volume":"47","author":"A Barre","year":"2018","unstructured":"Barre A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47(7):896\u2013905.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11\u201312","key":"783_CR45","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/apt.13813","volume":"44","author":"A Stallmach","year":"2016","unstructured":"Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, et al. Vedolizumab provides clinical benefit over 1\u00a0year in patients with active inflammatory bowel disease: a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44(11\u201312):1199\u2013212.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"783_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MIB.0000000000001039","volume":"23","author":"U Kopylov","year":"2017","unstructured":"Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the Israeli real-world experience. Inflamm Bowel Dis. 2017;23(3):404\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"783_CR47","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","volume":"21","author":"E Shelton","year":"2015","unstructured":"Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879\u201385.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"783_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","volume":"17","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, et al. Rapid response to vedolizumab therapy in biologic-na\u00efve patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130\u2013138.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"783_CR49","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/apt.13408","volume":"42","author":"V Jairath","year":"2015","unstructured":"Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42(10):1200\u201310.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"783_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.13001","volume":"41","author":"R Khanna","year":"2015","unstructured":"Khanna R, Zou G, D\u2019Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity. Aliment Pharmacol Ther. 2015;41(1):77\u201386.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"783_CR51","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","volume":"12","author":"BG Feagan","year":"2018","unstructured":"Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, et al. Efficacy of vedolizumab in fistulising Crohn\u2019s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12(5):621\u20136.","journal-title":"J Crohns Colitis."},{"issue":"5","key":"783_CR52","doi-asserted-by":"publisher","first-page":"S396","DOI":"10.1016\/S0016-5085(17)31562-7","volume":"152","author":"S Tadbiri","year":"2017","unstructured":"Tadbiri S, Grimaud J-C, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel diseases: a post hoc analysis of the observ-IBD cohort of the Getaid. Gastroenterology. 2017;152(5):S396.","journal-title":"Gastroenterology"},{"issue":"1","key":"783_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","volume":"13","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Sandborn WJ, Colombel JF, O\u2019Byrne S, Khalid JM, Kempf C, et al. Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. J Crohns Colitis. 2019;13(1):50\u20137.","journal-title":"J Crohns Colitis."},{"key":"783_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy065","author":"MC Dubinsky","year":"2018","unstructured":"Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, et al. Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018. https:\/\/doi.org\/10.1093\/ibd\/izy065 (Epub 13 Apr 2018).","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"783_CR55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","volume":"63","author":"M Fleisher","year":"2018","unstructured":"Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, et al. Effects of Vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018;63(4):825\u201333.","journal-title":"Dig Dis Sci"},{"issue":"20","key":"783_CR56","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med"},{"issue":"4","key":"783_CR57","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med. 2005;353(4):362\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"783_CR58","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","volume":"190","author":"KG Haanstra","year":"2013","unstructured":"Haanstra KG, Hofman SO, Est\u00eav\u00e3o DML, Blezer EL, Bauer J, Yang L-L, et al. Antagonizing the \u03b14\u03b21 integrin, but not \u03b14\u03b27, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013;190(5):1961\u201373.","journal-title":"J Immunol."},{"key":"783_CR59","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fimmu.2017.00764","volume":"8","author":"F Fuchs","year":"2017","unstructured":"Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, et al. clinical response to vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles. Front Immunol. 2017;8:764.","journal-title":"Front Immunol."},{"issue":"5","key":"783_CR60","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2019Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"1","key":"783_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.14075","volume":"46","author":"WA Bye","year":"2017","unstructured":"Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3\u201315.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"783_CR62","doi-asserted-by":"publisher","first-page":"S977","DOI":"10.1016\/S0016-5085(16)33311-X","volume":"150","author":"AHM Ladd","year":"2016","unstructured":"Ladd AHM, Scott FI, Grace R, Bownik H, Lichtenstein GR. Safety of vedolizumab in inflammatory bowel disease patients: real world experience from a large university practice. Gastroenterology. 2016;150(4):S977.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"783_CR63","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1093\/ecco-jcc\/jjx180.494","volume":"12","author":"P Kotze","year":"2018","unstructured":"Kotze P, Mckenna N, Ma C, Almutairdi A, Raffals L, Loftus E Jr, et al. Vedolizumab and early postoperative complications in non-intestinal surgery: a case-matched analysis. J Crohns Colitis. 2018;12(Suppl 1):S290.","journal-title":"J Crohns Colitis."},{"issue":"12","key":"783_CR64","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1097\/MIB.0000000000001248","volume":"23","author":"AL Lightner","year":"2017","unstructured":"Lightner AL, McKenna NP, Moncrief S, Pemberton JH, Raffals LE, Mathis KL. Surgical outcomes in vedolizumab-treated patients with ulcerative colitis. Inflamm Bowel Dis. 2017;23(12):2197\u2013201.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"783_CR65","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/apt.14459","volume":"47","author":"A Lightner","year":"2018","unstructured":"Lightner A, McKenna N, Tse C, Raffals L, Loftus E Jr, Mathis K. Postoperative outcomes in vedolizumab-treated Crohn\u2019s disease patients undergoing major abdominal operations. Aliment Pharmacol Ther. 2018;47(5):573\u201380.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"783_CR66","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/ibd\/izx076","volume":"24","author":"AL Lightner","year":"2018","unstructured":"Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, et al. Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: retrospective multicenter cohort study. Inflamm Bowel Dis. 2018;24(4):871\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"783_CR67","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ecco-jcc\/jjy022","volume":"12","author":"CCY Law","year":"2018","unstructured":"Law CCY, Narula A, Lightner AL, McKenna NP, Colombel J-F, Narula N. Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12(5):538\u201345.","journal-title":"J Crohns Colitis."},{"issue":"Suppl 1","key":"783_CR68","first-page":"S47","volume":"23","author":"B Shen","year":"2017","unstructured":"Shen B, Blake A, Lasch K, Palo W, Smyth M, Bhayat F. Vedolizumab use in patients with IBD undergoing surgery: a summary from clinical trials and post-marketing experience. Inflamm Bowel Dis. 2017;23(Suppl 1):S47.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"783_CR69","doi-asserted-by":"publisher","first-page":"S019","DOI":"10.1093\/ecco-jcc\/jjx180.025","volume":"12","author":"D Faleck","year":"2018","unstructured":"Faleck D, Shashi P, Meserve J, Rahal M, Kadire S, Tran G, et al. Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis. J Crohns Colitis. 2018;12(Suppl 1):S019.","journal-title":"J Crohns Colitis."},{"issue":"Suppl 1","key":"783_CR70","first-page":"18","volume":"12","author":"M Bohm","year":"2018","unstructured":"Bohm M, Sagi SV, Fischer M, Kadire S, Tran G, Rahal M, et al. Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn\u2019s disease: a multicentre consortium propensity score-matched analysis. J Crohns Colitis. 2018;12(Suppl 1):18.","journal-title":"J Crohns Colitis."},{"issue":"Suppl 1","key":"783_CR71","doi-asserted-by":"publisher","first-page":"S036","DOI":"10.1093\/ecco-jcc\/jjx180.046","volume":"12","author":"D Lukin","year":"2018","unstructured":"Lukin D, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, et al. Comparative safety profile of vedolizumab and tumour necrosis factor\u2013antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. J Crohns Colitis. 2018;12(Suppl 1):S036.","journal-title":"J Crohns Colitis."},{"issue":"2","key":"783_CR72","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/apt.14422","volume":"47","author":"S Singh","year":"2018","unstructured":"Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162\u201375.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"783_CR73","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","volume":"148","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344\u201354.e5.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"783_CR74","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1093\/ecco-jcc\/jjx002.430","volume":"11","author":"G Hather","year":"2017","unstructured":"Hather G, Curtis R, Minda K, Zouraq IA, Khalid JM. Indirect comparison of two novel biologics for the treatment of Crohn\u2019s disease: network-meta analysis of ustekinumab vs vedolizumab. J Crohns Colitis. 2017;11(Suppl 1):S232\u20133.","journal-title":"J Crohns Colitis."},{"issue":"Suppl 1","key":"783_CR75","first-page":"44","volume":"23","author":"S Singh","year":"2017","unstructured":"Singh S, Fumery M, Dulai P, Murad M, Sandborn W. Comparative efficacy of pharmacological agents for moderate-severe Crohn\u2019s disease in patients with prior exposure to anti-TNF agents: a network meta-analysis. Inflamm Bowel Dis. 2017;23(Suppl 1):44.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"783_CR76","first-page":"262","volume":"1","author":"A Varu","year":"2018","unstructured":"Varu A, Palimaka S, Hutton B, Wilson FR, Dyrda P, Naessens D, et al. Treatment sequence network-meta analysis in Crohn\u2019s disease. Can J Gastroenterol Hepatol. 2018;1(Suppl 1):262\u20133.","journal-title":"Can J Gastroenterol Hepatol."},{"issue":"10","key":"783_CR77","first-page":"617","volume":"12","author":"Y Schneider","year":"2016","unstructured":"Schneider Y, Saumoy M, Cohen-Mekelburg S, Steinlauf AF, Scherl EJ. The cost-effectiveness of vedolizumab for inflammatory bowel disease: a review of the current literature. Gastroenterol Hepatol. 2016;12(10):617\u201321.","journal-title":"Gastroenterol Hepatol"},{"key":"783_CR78","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","volume":"53","author":"S Schreiber","year":"2018","unstructured":"Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048\u201364.","journal-title":"J Gastroenterol"},{"issue":"Suppl 1","key":"783_CR79","first-page":"S416","volume":"10","author":"M Chaparro","year":"2016","unstructured":"Chaparro M, Sierra-Ausin M, Mesonero F, Maroto N, Fernandez de Castro C, Garc\u00eda-S\u00e1nchez V, et al. Effectiveness and safety of vedolizumab for the induction of remission in inflammatory bowel disease. Inflamm Bowel Dis. 2016;10(Suppl 1):S416\u20137.","journal-title":"Inflamm Bowel Dis."},{"issue":"4 suppl 1","key":"783_CR80","doi-asserted-by":"publisher","first-page":"S974","DOI":"10.1016\/S0016-5085(16)33301-7","volume":"150","author":"K Chaudrey","year":"2016","unstructured":"Chaudrey K, Whitehead D, Dulai PS, Peerani F, Narula N, Hudesmanet D, et al. Safety of vedolizumab in inflammatory bowel disease in a multi-center real world consortium. Gastroenterology. 2016;150(4 suppl 1):S974.","journal-title":"Gastroenterology."},{"issue":"Suppl 1","key":"783_CR81","first-page":"S388","volume":"9","author":"B Christensen","year":"2015","unstructured":"Christensen B, Goeppinger SR, Colman R, Siddiqui D, Yarur A, Bochenek AA. Post-marketing experience of vedolizumab for IBD: The University of Chicago experience. J Crohns Colitis. 2015;9(Suppl 1):S388\u20139.","journal-title":"J Crohns Colitis."},{"issue":"suppl 1","key":"783_CR82","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/ecco-jcc\/jjx002.060","volume":"11","author":"P Dulai","year":"2017","unstructured":"Dulai P, Meserve J, Hartke J, Chilukuri P, Chaudrey K, Koliani-Pace JL, et al. Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium. J Crohns Colitis. 2017;11(suppl 1):S40\u20131.","journal-title":"J Crohns Colitis."},{"key":"783_CR83","unstructured":"Hoog C, Eberhardson M, Almer S. P419. Efficacy of vedoli-zumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies. Presented at: European Crohn\u2019s and Colitis Organisation Congress, March 16\u201319, 2016, Amsterdam, The Netherlands."},{"issue":"suppl 1","key":"783_CR84","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1093\/ecco-jcc\/jjx002.649","volume":"11","author":"MV Lenti","year":"2017","unstructured":"Lenti MV, Levison S, Eliadou E, et al. P525. Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of \u2018\u2018real world data\u2019\u2019 from the UK. J Crohns Colitis. 2017;11(suppl 1):S347.","journal-title":"J Crohns Colitis."},{"issue":"suppl 1","key":"783_CR85","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/01.MIB.0000480188.00054.c2","volume":"22","author":"C Mankongpaisarnrung","year":"2016","unstructured":"Mankongpaisarnrung C, Mattar M, Charabaty A. Single-center experience: vedolizumab in patients with Crohn\u2019s disease and ulcerative colitis at Georgetown University Hospital. Inflamm Bowel Dis. 2016;22(suppl 1):S32.","journal-title":"Inflamm Bowel Dis."},{"issue":"suppl 1","key":"783_CR86","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1093\/ecco-jcc\/jjx002.572","volume":"11","author":"RWM Pauwels","year":"2017","unstructured":"Pauwels RWM, De Vries AC, Van der Woude CJ. P447. Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn\u2019s disease. J Crohns Colitis. 2017;11(suppl 1):S305.","journal-title":"J Crohns Colitis."},{"issue":"3","key":"783_CR87","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/flgastro-2016-100720","volume":"8","author":"MA Samaan","year":"2017","unstructured":"Samaan MA, Pavlidis P, Johnston E, et al. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2017;8(3):196\u2013202.","journal-title":"Frontline Gastroenterol."},{"issue":"5 suppl 1","key":"783_CR88","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0016-5085(17)30608-X","volume":"152","author":"R Shivashankar","year":"2017","unstructured":"Shivashankar R, Mendoza Ladd AH, Grace R, et al. Effect of vedolizumab dose escalation on recapturing response in patients with inflammatory bowel disease. Gastroenterology. 2017;152(5 suppl 1):S77.","journal-title":"Gastroenterology."},{"issue":"5 suppl","key":"783_CR89","first-page":"A3","volume":"4","author":"B Ungar","year":"2016","unstructured":"Ungar B, Kopylov U, Waterman M, et al. Early vedolizumab drug levels and induction success in patients with inflammatory bowel disease. United European Gastroenterol J. 2016;4(5 suppl):A3.","journal-title":"United European Gastroenterol J."},{"issue":"7","key":"783_CR90","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/lt.24757","volume":"23","author":"AP Wright","year":"2017","unstructured":"Wright AP, Fontana RJ, Stidham RW. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation. Liver Transpl. 2017;23(7):968\u201371.","journal-title":"Liver Transpl."},{"issue":"suppl 1","key":"783_CR91","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1093\/ecco-jcc\/jjx002.626","volume":"11","author":"P Zezos","year":"2017","unstructured":"Zezos P, Kabakchiev B, Weizman AV, et al. P502. Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment. J Crohns Colitis. 2017;11(suppl 1):S334\u20135.","journal-title":"J Crohns Colitis."},{"issue":"suppl 1","key":"783_CR92","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/01.MIB.0000480161.93298.10","volume":"22","author":"M Abramowitz","year":"2016","unstructured":"Abramowitz M, Dale M, Saumoy M, et al. Harvey-Bradshaw index captures clinical efficacy of vedolizumab induction therapy for active Crohn\u2019s disease. Inflamm Bowel Dis. 2016;22(suppl 1):S27.","journal-title":"Inflamm Bowel Dis."},{"issue":"suppl 1","key":"783_CR93","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.14309\/00000434-201610001-00600","volume":"111","author":"A Blum","year":"2016","unstructured":"Blum A, Gregory N, Keyur P, et al. Vedolizumab for the treatment of Crohn\u2019s disease: experience in an inflammatory bowel disease clinical practice. Am J Gastroenterol. 2016;111(suppl 1):S276.","journal-title":"Am J Gastroenterol."},{"issue":"5 suppl","key":"783_CR94","first-page":"A3","volume":"4","author":"A Gils","year":"2016","unstructured":"Gils A, Dreesen E, Compernolle G, et al. Vedolizumab exposure correlates with clinical, biological and endoscopic outcome in patients with inflammatory bowel disease. United Eur Gas-troenterol J. 2016;4(5 suppl):A3.","journal-title":"United Eur Gas-troenterol J."},{"issue":"suppl 1","key":"783_CR95","doi-asserted-by":"crossref","first-page":"S826","DOI":"10.14309\/00000434-201510001-01949","volume":"110","author":"S Glover","year":"2015","unstructured":"Glover S, Edminster T, Garcia L, et al. Efficacy of vedolizumab in Crohn\u2019s disease after at least 14 weeks of therapy as measured by HBI scores. Am J Gastroenterol. 2015;110(suppl 1):S826.","journal-title":"Am J Gastroenterol."},{"issue":"5 suppl","key":"783_CR96","first-page":"A452","volume":"4","author":"M Vos De","year":"2016","unstructured":"De Vos M, Dhooghe B, Vermeire S, et al. P0868. Open label observational study evaluating the effect of induction therapy with vedolizumab in patients with moderate to severe inflam-matory bowel disease intolerant\/resistant to at least two bio-logicals. United Eur Gastroenterol J. 2016;4(5 suppl):A452.","journal-title":"United Eur Gastroenterol J"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-00783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-018-00783-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-00783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T04:17:05Z","timestamp":1694665025000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-018-00783-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-00783-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"4 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This narrative review was not funded by an external source.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Robert Battat has no conflicts to declare. Christopher Ma is supported by a Clinician Fellowship from the Canadian Association of Gastroenterology and the Canadian Institutes of Health Research. Vipul Jairath has received consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena Pharmaceuticals, Genetech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Robarts Clinical Trials, Topivert and Celltrion, and speaker\u2019s fees from Takeda, Janssen, Shire, Ferring, Abbvie and Pfizer. Reena Khanna has received consulting fees from AbbVie, Janssen, Pfizer, Takeda, and Robarts Clinical Trials Inc., and speaker\u2019s fees from AbbVie, Janssen, Shire, and Takeda. Brian G. Feagan has received grant\/research support from AbbVie Inc., Amgen Inc., AstraZeneca\/MedImmune Ltd, Atlantic Pharmaceuticals Ltd, Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc.\/Hoffmann-La Roche Ltd, Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC, Pfizer Inc., Receptos Inc.\/Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG and UCB; consulting fees from Abbott\/AbbVie, Ablynx, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Baxter Healthcare Corp., Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan\/Biogen, EnGene, Ferring Pharma, Roche\/Genentech, Galapagos, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Inception IBD Inc., Ironwood Pharma, Janssen Biotech (Centocor), JnJ\/Janssen, Kyowa Kakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Nextbiotix, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos, Roche\/Genentech, Salix Pharma, Serano, Shire, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd, Warner-Chilcott, Wyeth, Zealand and Zyngenia; speakers bureau fees from Abbott\/AbbVie, JnJ\/Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; advisory board fees from Abbott\/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan\/Biogen, Ferring, Galapagos, Genentech\/Roche, JnJ\/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG and UCB Pharma; and is a consultant (Senior Scientific Officer) for Robarts Clinical Trials, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}